FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793287493> ?p ?o ?g. }

• W2793287493 abstract "Background Carboxymaltoside-iron (CMI)and isomaltoside-iron (IMI)have both indications for the treatment of iron deficiency when oral preparations are ineffective or cannot be used. Purpose To describe the use of CMI and IMI, and to evaluate its effectiveness and cost in a tertiary-level hospital. Material and methods Retrospective observational study based on the analysis of the data obtained through the CMI and IMI prescriptions of 1 year. The main variable used to evaluate effectiveness was the percentage of patients with an increase in haemoglobin (HB) compared to baseline HB higher than 1 g/dL between 30 to 60 days’ post-administration. The mean increase in HB (g/dL) by cumulative dose in the same period of time was the second variable. A search was made on our system, and sex, dose, posology, prescribing service, treatment with erythropoiesis stimulating factors (ESF) and direct cost per cumulative dose. Results Thirty-one patients(13 females, 18 men) were treated with CMI and 35 (25 females and 10 men) with IMI. The median cumulative dose was 500 mg (500–1000) for CMI and 1000 (1000–1000) for IMI. The median cost per cumulative dose was €89 for CMI (89–178) and €148 (148–148) for IMI. Prescription services were: nephrology 25%, haematology 12.5%, cardiology 12.5%, digestive system 25%, surgery 6.25% and systemic diseases 18.75% for CMI compared to nephrology 45.45%, haematology 36.36% and cardiology 18.18% for IMI. The percentage of patients with an increase in HB compared to baseline HB higher than 1 g/dL:50% for CMI and 45.45% for IMI. Among patients on ESF treatment these percentages were 3125% for CMI and 27.27% for IMI. Mean increase of HB compared to baseline HB (g/dl) by cumulative dose: 1.04±2 for CMI and 0.73±1.29 for IMI (p=0.3) and among patients receiving ESF was 2.2±1.03 for CMI compared to 0.94±1.31 for IMI (p=0.046). Conclusion The effectiveness in the patients studied was higher with CMI than with IMI because better results were observed with a lower cumulative dose. It was also observed that the effectiveness was higher in patients receiving ESF for both compounds, and it was statistically significant among patients on ESF treatment. In terms of use, the service with the greatest number of prescriptions in both compounds was nephrology. No conflict of interest" @default.
• W2793287493 created "2018-03-29" @default.
• W2793287493 creator A5007576992 @default.
• W2793287493 creator A5021628112 @default.
• W2793287493 creator A5088934344 @default.
• W2793287493 creator A5090509338 @default.
• W2793287493 date "2018-03-01" @default.
• W2793287493 modified "2023-09-23" @default.
• W2793287493 title "4CPS-020 Use and effectiveness of carboxymaltose iron and isomaltoside iron" @default.
• W2793287493 doi "https://doi.org/10.1136/ejhpharm-2018-eahpconf.111" @default.
• W2793287493 hasPublicationYear "2018" @default.
• W2793287493 type Work @default.
• W2793287493 sameAs 2793287493 @default.
• W2793287493 citedByCount "0" @default.
• W2793287493 crossrefType "proceedings-article" @default.
• W2793287493 hasAuthorship W2793287493A5007576992 @default.
• W2793287493 hasAuthorship W2793287493A5021628112 @default.
• W2793287493 hasAuthorship W2793287493A5088934344 @default.
• W2793287493 hasAuthorship W2793287493A5090509338 @default.
• W2793287493 hasBestOaLocation W27932874932 @default.
• W2793287493 hasConcept C126322002 @default.
• W2793287493 hasConcept C141071460 @default.
• W2793287493 hasConcept C151032500 @default.
• W2793287493 hasConcept C167135981 @default.
• W2793287493 hasConcept C194409129 @default.
• W2793287493 hasConcept C2426938 @default.
• W2793287493 hasConcept C54847362 @default.
• W2793287493 hasConcept C71924100 @default.
• W2793287493 hasConcept C90924648 @default.
• W2793287493 hasConcept C98274493 @default.
• W2793287493 hasConceptScore W2793287493C126322002 @default.
• W2793287493 hasConceptScore W2793287493C141071460 @default.
• W2793287493 hasConceptScore W2793287493C151032500 @default.
• W2793287493 hasConceptScore W2793287493C167135981 @default.
• W2793287493 hasConceptScore W2793287493C194409129 @default.
• W2793287493 hasConceptScore W2793287493C2426938 @default.
• W2793287493 hasConceptScore W2793287493C54847362 @default.
• W2793287493 hasConceptScore W2793287493C71924100 @default.
• W2793287493 hasConceptScore W2793287493C90924648 @default.
• W2793287493 hasConceptScore W2793287493C98274493 @default.
• W2793287493 hasLocation W27932874931 @default.
• W2793287493 hasLocation W27932874932 @default.
• W2793287493 hasOpenAccess W2793287493 @default.
• W2793287493 hasPrimaryLocation W27932874931 @default.
• W2793287493 hasRelatedWork W2029025556 @default.
• W2793287493 hasRelatedWork W2086225073 @default.
• W2793287493 hasRelatedWork W2096416990 @default.
• W2793287493 hasRelatedWork W2121180312 @default.
• W2793287493 hasRelatedWork W2144971719 @default.
• W2793287493 hasRelatedWork W2145474852 @default.
• W2793287493 hasRelatedWork W2253612270 @default.
• W2793287493 hasRelatedWork W2327013745 @default.
• W2793287493 hasRelatedWork W2343441181 @default.
• W2793287493 hasRelatedWork W2416087924 @default.
• W2793287493 hasRelatedWork W2546477507 @default.
• W2793287493 hasRelatedWork W2555641278 @default.
• W2793287493 hasRelatedWork W2567843084 @default.
• W2793287493 hasRelatedWork W2581639209 @default.
• W2793287493 hasRelatedWork W2804356866 @default.
• W2793287493 hasRelatedWork W2811053369 @default.
• W2793287493 hasRelatedWork W2979997050 @default.
• W2793287493 hasRelatedWork W3096010167 @default.
• W2793287493 hasRelatedWork W3160338797 @default.
• W2793287493 hasRelatedWork W2310757701 @default.
• W2793287493 isParatext "false" @default.
• W2793287493 isRetracted "false" @default.
• W2793287493 magId "2793287493" @default.
• W2793287493 workType "article" @default.